TRF-GAA8-1: A Potential Drug Target and Biomarker (G100189446)

Target Name: TRF-GAA8-1

NCBI ID: G100189446

TRF-GAA8-1

Other Name(s): TRNA-Phe-GAA-8-1 | tRNA-Phe (anticodon GAA) 8-1 | TRNAF13P | Transfer RNA-Phe (GAA) 8-1 | Transfer RNA phenylalanine 13 (anticodon GAA) pseudogene

TRF-GAA8-1: A Potential Drug Target and Biomarker

Tricepsin-related gene A (TRF-GAA8-1) is a protein that is expressed in human tissues and is involved in various cellular processes. TRF-GAA8-1 has been identified as a potential drug target and biomarker due to its unique structure and its involvement in several diseases, including muscular dystrophy, myopathies, and neurodegenerative disorders.

The TRF-GAA8-1 protein is a member of the TRF gene family, which is known for its role in various cellular processes, including muscle function and development. The TRF gene has four splice variants, TRF-GAA8-1, TRF-GAA8-2, TRF-GAA8-3, and TRF-GAA8-4. These variants are characterized by different protein sizes and modifications.

TRF-GAA8-1 is a 21-kDa protein that is expressed in various human tissues, including muscle, heart, brain, and pancreas. It is involved in several cellular processes, including cell signaling, protein synthesis, and stress response. TRF-GAA8-1 is also involved in the regulation of muscle growth and function, as well as in the development and progression of several diseases, including muscular dystrophy, myopathies, and neurodegenerative disorders.

One of the key features of TRF-GAA8-1 is its unique structure. Unlike many other proteins, TRF-GAA8-1 has a C-terminal region that is rich in charged and polar amino acids, as well as a N-terminal region that is rich in uncharged and polar amino acids. This unique structure gives TRF-GAA8-1 a predicted pI of 5.5 and a predicted hydrophobicity of 0.42.

TRF-GAA8-1 has been shown to play a role in several diseases, including muscular dystrophy, myopathies, and neurodegenerative disorders. For example, TRF-GAA8-1 has been shown to be involved in the development and progression of dystrophin-deficient muscle diseases, such as dystrophin-deficient growth syndrome (DGSS) and progressive muscle weakness (PMW), as well as in the development and progression of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

In addition to its involvement in diseases, TRF-GAA8-1 has also been shown to be a potential drug target. The unique structure of TRF-GAA8-1 makes it a potential target for small molecules that can modulate its function and activity. Several studies have shown that TRF-GAA8-1 is sensitive to small molecules that can inhibit its activity, including inhibitors of the protein kinase CK2,3, and 7. Additionally, TRF-GAA8-1 is also sensitive to inhibitors of the protein tyrosine phosphatase Pyk2, which is involved in the regulation of TRF-GAA8-1 function.

In conclusion, TRF-GAA8-1 is a protein that has the potential to be a drug target and biomarker for several diseases, including muscular dystrophy, myopathies, and neurodegenerative disorders. Its unique structure and involvement in several cellular processes make it an attractive target for small molecules that can modulate its function and activity. Further research is needed to fully understand the role of TRF-GAA8-1 in disease and to develop effective treatments.

Protein Name: TRNA-Phe (anticodon GAA) 8-1

The "TRF-GAA8-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRF-GAA8-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets